What the Epithalon (AEDG) literature actually shows about telomerase, telomere length, melatonin and lifespan, in which models, and why most of it comes from a single research group.
Epithalon (also written Epitalon or Epithalone) is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly, often abbreviated AEDG. It was developed by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology, and over roughly three decades it has been studied in cell culture, rodents and a small number of primates for its reported effects on telomerase, pineal function and aging markers [2][9]. This guide walks through what each line of evidence shows, in which model, and where the open questions sit. One point deserves emphasis from the start: most of the published work comes from one research network, and independent replication is only beginning.
Epithalon traces back to Epithalamin, a polypeptide extract of bovine pineal gland that the same group studied as a so-called peptide bioregulator. AEDG was synthesized on the basis of Epithalamin's amino acid composition, and the group later reported detecting the sequence within the pineal polypeptide complex itself [9]. Because it is only four residues long (molecular weight 390.35), it is far easier to synthesize and characterize than the parent extract, which is why it became the working tool for this line of research.
Telomeres are repetitive DNA sequences (TTAGGG in humans) that cap the ends of chromosomes. Because DNA polymerase cannot fully copy the lagging-strand end, telomeres shorten a little with each division. When they become critically short, cells enter replicative senescence, a stable growth arrest that contributes to tissue aging.
Telomerase, a reverse transcriptase whose catalytic subunit is encoded by the TERT gene (hTERT in humans), can add telomeric repeats back. It is active in germ cells, stem cells and most cancers, but repressed in most adult somatic cells. A compound that switches telomerase on in normal cells is therefore scientifically interesting and, because cancers depend on telomere maintenance, something to study with care.
In a 2003 report, adding Epithalon to telomerase-negative human fetal fibroblasts induced expression of the telomerase catalytic subunit, measurable telomerase activity and telomere elongation [1]. A 2004 follow-up used fetal lung fibroblasts that normally stopped dividing at the 34th passage, with shorter telomeres than at early passages. Cells exposed to the peptide elongated their telomeres to a length comparable to early passages and went on to 44 passages, ten more divisions than controls, while still dividing when the report was written [5]. Both are brief communications from the same laboratory using one cell source, which limits how far they can be generalized.
The most useful recent addition comes from a group at Brunel University London with no stated ties to the original developers [6]. They exposed normal epithelial and fibroblast cells and two breast cancer cell lines (21NT and BT474) to Epithalon and measured telomere length, hTERT mRNA, telomerase activity and markers of ALT (alternative lengthening of telomeres). In the normal cells, telomeres lengthened in a concentration-dependent way through hTERT and telomerase upregulation, which broadly supports the earlier Russian findings. In the cancer lines, telomeres also lengthened, but largely through ALT activation, a telomerase-independent mechanism [6]. That result is a reminder that the same peptide can act through different routes depending on cell type, and that telomere maintenance in malignant cells is a question to measure directly rather than assume away.
Given its pineal origin, Epithalon has also been studied for effects on melatonin. In rat pinealocyte culture, it increased synthesis of arylalkylamine N-acetyltransferase (AANAT, a key enzyme in melatonin production) and of the transcription factor pCREB, and raised melatonin in the culture medium; adding norepinephrine alongside the peptide potentiated those effects [8]. In senescent female rhesus monkeys, the group reported that Epithalon stimulated evening melatonin production and normalized the circadian rhythm of cortisol secretion [7]. The primate work is valuable because few peptide studies reach non-human primates, but it involved small numbers of animals and has not been independently repeated.
How a four-residue peptide would change telomerase or AANAT expression is not established. The Khavinson group has proposed that short peptides enter the nucleus and interact with chromatin. In a 2020 study in human gingival mesenchymal stem cells, AEDG increased mRNA for the neurogenic markers Nestin, GAP43, beta-III tubulin and Doublecortin by 1.6 to 1.8 times, and molecular modelling suggested the peptide could bind histones H1/3 and H1/6 at DNA-interacting sites [10]. The modelling is a hypothesis generator rather than a demonstrated binding event, and a 2025 review from an unaffiliated group in Warsaw concluded that it remains uncertain whether the effects described so far are Epithalon's only mechanisms of action [9].
The most frequently quoted lifespan data come from a 2003 study in female outbred Swiss-derived SHR mice, 54 per group, exposed to the peptide in monthly courses from 3 months of age until natural death [4]. It is worth reading the findings exactly, because they are often overstated:
A separate study in one-year-old female C3H/He mice followed animals for 6.5 months and reported fewer mice with malignant tumors in the Epithalon group, with no metastases found, compared with metastases in 3 of 9 tumor-bearing controls [3]. The numbers are small. The group's own 2010 review summarizes decades of rodent work across several peptide bioregulators, including lifespan and carcinogenesis models [2].
Telomere work usually combines several readouts, because each has blind spots. Common choices include telomerase activity by TRAP assay, hTERT expression by RT-qPCR, telomere length by qPCR or by fluorescence-based methods, and immunofluorescence, as used in the 2025 study [6]. Where cancer lines are involved, ALT markers belong in the panel. Senescence studies track population doublings and senescence-associated markers across matched passages. Pineal studies measure melatonin in culture medium alongside AANAT expression [8].
Good designs match passage number between arms, include telomerase-positive and telomerase-negative reference cells, score imaging blind, and report the peptide's source, lot and analytical purity so that others can reproduce the material as well as the method.
Epithalon is a small, hydrophilic peptide (C14H22N4O9) that dissolves readily in water. Store the lyophilized powder at -20 °C, sealed and protected from moisture and light. Let the vial reach room temperature before opening so condensation does not form on the powder. Prepare stock solutions in sterile water or the buffer your assay requires, divide them into single-use aliquots and keep them frozen, which avoids repeated freezing and thawing. Record the lot number with every experiment.
Northbridge Research Labs sends every batch for independent third-party testing. The certificate for Epithalon lot ET50001 (50 mg, tested August 2026) reports 99.89% purity and is published on our COA page, where certificates are posted online rather than printed in the box.
Note: Epithalon from Northbridge Research Labs is supplied for laboratory research use only. It is not for human or veterinary use, and nothing in this article describes a use in people or animals outside a controlled research setting.
Studied compound
Epithalon
The same material this research covers — 99%+ purity, independently tested, with the certificate for each batch published online.
How a single trans-3-hexenoyl group turns native GHRH into a longer-lived analogue, what the phase 3 and liver-fat trials actually found, what preclinical work showed, and how to handle tesamorelin in the lab.
What sermorelin acetate is, where the 29-residue fragment came from, how it acts at the GHRH receptor, how it compares with native GHRH, tesamorelin, CJC-1295 and ipamorelin, and how to handle it in the lab.
How retatrutide-type triple agonism at the GLP-1, GIP and glucagon receptors was designed, what the published rodent and phase 2 literature reports, and which questions remain open for laboratory study.
Research Use Only: The information in this article is for educational and research purposes only. All products mentioned are intended for laboratory research use only and are not approved for human or veterinary use.